Fedratinib
Sign in to save this workspacePrimary targets: JAK2 · FDA status: FDA Approved
Selectivity scorecard
KISS
96.21
Gini
0.576
CATDS
0.010
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Fedratinib. Strongest target: RET at 99.9% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | RET | 99.9% | 0.1% |
| 2 | JAK2 | 99.4% | 0.6% |
| 3 | FLT3 | 98.2% | 1.8% |
| 4 | ZIPK_DAPK3 | 97.7% | 2.3% |
| 5 | DAPK1 | 97.3% | 2.6% |
| 6 | SIK2 | 96.8% | 3.2% |
| 7 | DDR1 | 95.2% | 4.8% |
| 8 | FAK_PTK2 | 94.4% | 5.6% |
| 9 | JAK1 | 94.2% | 5.8% |
| 10 | TYK2 | 93.6% | 6.4% |
| 11 | ARK5_NUAK1 | 93.5% | 6.5% |
| 12 | ACK1 | 93.4% | 6.6% |
| 13 | AURORA_C | 92.1% | 7.9% |
| 14 | ROS_ROS1 | 90.7% | 9.3% |
| 15 | STK22D_TSSK1 | 90.5% | 9.5% |
| 16 | SIK1 | 88.8% | 11.2% |
| 17 | FLT4_VEGFR3 | 88.4% | 11.6% |
| 18 | DDR2 | 88.3% | 11.7% |
| 19 | LCK | 87.1% | 12.9% |
| 20 | YES_YES1 | 86.8% | 13.2% |
Selectivity landscape
Where Fedratinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Fedratinib.
Annotations
Sign in to read and post annotations.
Loading…